RIGEL PHARMACEUTICALS INCRIGLEarnings & Financial Report
Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.
RIGL Q4 FY2025 Key Financial Metrics
Revenue
$69.8M
Gross Profit
$63.8M
Operating Profit
$23.2M
Net Profit
$268.1M
Gross Margin
91.5%
Operating Margin
33.2%
Net Margin
384.0%
YoY Growth
21.2%
EPS
$14.11
RIGEL PHARMACEUTICALS INC Q4 FY2025 Financial Summary
RIGEL PHARMACEUTICALS INC reported revenue of $69.8M (up 21.2% YoY) for Q4 FY2025, with a net profit of $268.1M (up 1769.2% YoY) (384.0% margin). Cost of goods sold was $6.0M, operating expenses totaled $40.7M.
Key Financial Metrics
| Total Revenue | $69.8M |
|---|---|
| Net Profit | $268.1M |
| Gross Margin | 91.5% |
| Operating Margin | 33.2% |
| Report Period | Q4 FY2025 |
RIGEL PHARMACEUTICALS INC Annual Revenue by Year
RIGEL PHARMACEUTICALS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $294.3M).
RIGEL PHARMACEUTICALS INC Quarterly Revenue & Net Profit History
RIGEL PHARMACEUTICALS INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $69.8M | +21.2% | $268.1M | 384.0% |
| Q3 FY2025 | $69.5M | +25.6% | $27.9M | 40.2% |
| Q2 FY2025 | $101.7M | +176.0% | $59.6M | 58.6% |
| Q1 FY2025 | $53.3M | +80.6% | $11.4M | 21.5% |
| Q4 FY2024 | $57.6M | +60.9% | $14.3M | 24.9% |
| Q3 FY2024 | $55.3M | +96.6% | $12.4M | 22.5% |
| Q2 FY2024 | $36.8M | +37.0% | $-1.0M | -2.8% |
| Q1 FY2024 | $29.5M | +13.3% | $-8.2M | -27.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29.5M | $36.8M | $55.3M | $57.6M | $53.3M | $101.7M | $69.5M | $69.8M |
| YoY Growth | 13.3% | 37.0% | 96.6% | 60.9% | 80.6% | 176.0% | 25.6% | 21.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $126.5M | $128.4M | $139.4M | $164.0M | $176.0M | $206.7M | $242.5M | $513.6M |
| Liabilities | $158.2M | $158.3M | $154.1M | $160.7M | $157.4M | $124.8M | $124.9M | $122.1M |
| Equity | $-31.7M | $-29.9M | $-14.6M | $3.3M | $18.6M | $81.9M | $117.6M | $391.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.0M | $302000 | $21.7M | $14.5M | $-893000 | $30.5M | $24.0M | $22.0M |